Skip to main content
Contact Us
Sign Up
Subscriber Sign In
English
日本語
navigation
Search
What We Do
Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
About Vantage
Editorial team
Products & Services
Consensus Forecasts
Pharma
EvaluatePharma
EvaluatePharma Vision
Custom Solutions
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Client Success
Customer Testimonials
Thought Leadership
English
日本語
About Us
Media Centre
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Policy & Pricing
Policy & Regulation
Pricing
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Primary tabs
View
(active tab)
Repligen
October 11, 2016
Therapy focus – Spinal muscular atrophy pipeline awaits nusinersen news
September 01, 2016
Therapy focus – Clinging to options in Friedreich’s ataxia
February 02, 2015
Roche’s muscle forces out early competitor
January 16, 2015
Roche muscles into the lead in rare wasting disease
March 14, 2014
A low-key breakthrough in spinal muscular atrophy
January 04, 2013
Pfizer licenses Repligen’s SMA drug at phase I, but still trails
November 30, 2011
Therapeutic Focus - Roche ups big pharma stakes in spinal muscular atrophy
March 15, 2011
EP Vantage Interview - Pancreatic imaging agent a balm for Repligen
March 08, 2011
Repligen has one more chance to prove value
May 20, 2010
Therapeutic focus - Friedreich's ataxia a goal with few shots
April 14, 2008
RepliGen's Orencia royalty guidance looks lofty
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 31, 2019
Vantage Pharma, Biotech & Medtech Half-Year Review 2019
February 26, 2019
Vantage Pharma, Biotech and Medtech 2018 in Review
Editor's Picks
October 22, 2019
Shock revelation sees Biogen erase its aducanumab losses
October 22, 2019
Vertex’s double cystic fibrosis surprise
October 23, 2019
Bristol might play a role in front-line lung cancer after all
October 23, 2019
Bloated on arrival? Biotech's weightiest new issues
October 14, 2019
Uncovering biopharma’s hidden treasures
